Based on the Ajanta Pharma Limited stock forecast from 3 analysts, the average analyst target price for Ajanta Pharma Limited is INR 2,872.75 over the next 12 months. Ajanta Pharma Limited’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Ajanta Pharma Limited is Slightly Bullish , which is based on 9 positive signals and 5 negative signals. At the last closing, Ajanta Pharma Limited’s stock price was INR 2,790.40. Ajanta Pharma Limited’s stock price has changed by +3.56% over the past week, +0.81% over the past month and +30.78% over the last year.
No recent analyst target price found for Ajanta Pharma Limited
No recent average analyst rating found for Ajanta Pharma Limited
Company Overview Ajanta Pharma Limited
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India. Read Less
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, op...Read More
Frequently Asked Questions About Ajanta Pharma Limited (AJANTPHARM:NSE) Stock
Based on ratings from 3 analysts Ajanta Pharma Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, 2 sell and hold ratings.
AJANTPHARM:NSE stock's dividend yield is 2.06%.
Our analysis grades AJANTPHARM:NSE stock's dividend yield at A. This means that AJANTPHARM:NSE stock's dividend yield is above 95% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a good dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is INR 2,872.75 over the next 12 months. The maximum analyst target price is INR 3455 while the minimum anlayst target price is INR 2288.
AJANTPHARM:NSE stock's Price/Earning ratio is 36.63.
Our analysis grades AJANTPHARM:NSE stock's Price / Earning ratio at F. This means that AJANTPHARM:NSE stock's Price/Earning ratio is above 52% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a overvalued for its sector.
The last closing price of AJANTPHARM:NSE's stock was INR 2,790.40.
The most recent market capitalization for AJANTPHARM:NSE is INR 327.64B.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is projected at INR 2,872.75 over the next 12 months.
This means that AJANTPHARM:NSE's stock price may go up by +2.95% over the next 12 months.
We can't find any ETFs which contains Ajanta Pharma Limited's stock.
As per our most recent records Ajanta Pharma Limited has 8,073 Employees.
Ajanta Pharma Limited's registered address is Ajanta House, Mumbai, India, 400067.
You can get more information about it from Ajanta Pharma Limited's website at https://www.ajantapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Ajanta Pharma Limited (AJANTPHARM:NSE) Stock
Based on ratings from 3 analysts Ajanta Pharma Limited's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, 2 sell and hold ratings.
AJANTPHARM:NSE stock's dividend yield is 2.06%.
Our analysis grades AJANTPHARM:NSE stock's dividend yield at A. This means that AJANTPHARM:NSE stock's dividend yield is above 95% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a good dividend stock for its sector.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is INR 2,872.75 over the next 12 months. The maximum analyst target price is INR 3455 while the minimum anlayst target price is INR 2288.
AJANTPHARM:NSE stock's Price/Earning ratio is 36.63.
Our analysis grades AJANTPHARM:NSE stock's Price / Earning ratio at F. This means that AJANTPHARM:NSE stock's Price/Earning ratio is above 52% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSE exchange.
Based on this AJANTPHARM:NSE may be a overvalued for its sector.
The last closing price of AJANTPHARM:NSE's stock was INR 2,790.40.
The most recent market capitalization for AJANTPHARM:NSE is INR 327.64B.
Based on targets from 3 analysts, the average taret price for AJANTPHARM:NSE is projected at INR 2,872.75 over the next 12 months.
This means that AJANTPHARM:NSE's stock price may go up by +2.95% over the next 12 months.
We can't find any ETFs which contains Ajanta Pharma Limited's stock.
As per our most recent records Ajanta Pharma Limited has 8,073 Employees.
Ajanta Pharma Limited's registered address is Ajanta House, Mumbai, India, 400067.
You can get more information about it from Ajanta Pharma Limited's website at https://www.ajantapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AJANTPHARM:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
